Bioventus

Q2 FY2026 EarningsQ2 FY26 results were mixed, with revenue of $153.2M slightly missing the $155.6M consensus (-1.56%), while Adjusted EPS of $0.22 beat the $0.218 mean. Growth was driven by an 11.5% YoY surge in Pain Treatments, offset by declines in Surgical Solutions (-4.5%) and Restorative Therapies (-2.4%). Management reaffirmed FY26 guidance and, notably, initiated a review of strategic alternatives following unsolicited acquisition interest.